News
-
November 24th, 2023 - Press notes
33 new research projects received funding of up to 500,000 euros or up to one million euros in the sixth edition of the CaixaResearch Health Research call, promoted by the "la Caixa" Foundation. In total, 25.3 million euros in grants.
The call supports basic, clinical, or translational research projects with scientific excellence and social impact in cardiovascular diseases, infections, oncology, and neurosciences. It also supports projects developing enabling technologies in these areas.
Among the selected projects is one led by Dr. Toni Celià-Terrassa to advance the understanding of metastasis and its coevolution with the immune system. There are also two other projects with the participation of researchers from the Hospital del Mar, Dr. Víctor Pérez, and Dr. Arnau Busquets.
more information
-
November 17th, 2023 - Press notes
Researchers from the Hospital del Mar Research Institute have published a new article in Microbiology Spectrum proposing a novel approach to treating pneumonia caused by antibiotic-resistant Pseudomonas aeruginosa bacteria. The study suggests that increasing the dose of the antibiotic colistin may not only be ineffective but could also increase patient mortality
For this reason, the researchers advocate for using nebulized administration of the treatment instead of intravenous administration. This approach achieves higher concentrations in the lungs, where the infection is located, without causing toxic colistin concentrations in the blood
The World Health Organization considers antibiotic resistance among the top 10 global public health threats
more information
-
November 13th, 2023 - COVID-19
We encourage everyone worldwide to join the ALS cause by supporting it with their contributions to professionals in their fight against a disease that challenges hope.
more information
-
October 26th, 2022 - Press notes
A study involving the Hospital del Mar Research Institute, the Vall d'Hebron Institut d'Oncologia, IDIBELL, and the Institut Català d'Oncologia suggests that combining chemotherapy with drugs that can inhibit two cell signaling pathways involved in tumor progression may aid in treatment.
The research has analyzed the interaction of the protein IKKα with these pathways, known for their ability to promote the proliferation of tumor cells. This combination has the advantage of reducing treatment toxicity.
The study opens the door to new approaches for tumors with the presence of this protein. It is published in the EMBO Journal.
more information
-
September 27, 2023 - Press notes
Research conducted in a mouse model identifies the neurobiological mechanism responsible for alterations in the memory of young individuals exposed to alcohol during pregnancy and lactation. This study proposes a therapy that can reverse the deficit, paving the way for treating a disorder that is underdiagnosed in humans.
more information
-
September 18, 2023 - Press notes
Researchers from the UAB, the Gregorio Marañón Health Research Institute, and the Hospital del Mar Research Institute have published the first article reviewing research conducted to date on the neurobiological adaptation of women to motherhood by analysing the relation of hormones, brain and behaviour during pregnancy and the postpartum period.
The findings support the hypothesis that fluctuating hormones, mainly estrogens, are related to changes in the human brain structure, but what is yet to be determined is how this influences neuroplasticity and maternal behaviour.
The article sets a roadmap for future research projects and demonstrates the scarcity of research conducted until now in women, essential due to the differences existing in the sexual hormones of each species.
more information
-
September 7, 2023 - Press notes
Overall, health has worsened across the population, especially regarding anxiety and depression, as well as pain and discomfort. But the effects of the pandemic have hit educated women especially hard, narrowing their health disparities with population groups with a lower education after initial home confinement.
The researchers attribute this development to the negative effect of teleworking on the health of people who worked from home and had to care for family members. At the same time, there may have been a positive effect of government measures to mitigate the economic impact of the pandemic among more disadvantaged groups.
The work is part of the MINDCOVID project, and was based on telephone interview surveys of 2,000 people. It is published in the International Journal for Equity in Health.
more information
-
August 10, 2023 - Press notes
A team from the Hospital del Mar Research Institute has, for the first time, detected fetal DNA in the olfactory neuroepithelium of women who have given birth to a boy. A new study will now be launched, which will also analyze female fetal DNA.
The team of researchers has been able to confirm that women with depression had much lower levels of cells from newborns than those who were not suffering from this disorder.
This discovery paves the way to studying the DNA exchange between the mother and the fetus during pregnancy as a factor that protects women against depression, as well as its relationship with other psychiatric disorders.
more information
-
July, 31st 2023 - Press notes
When spinal deformity corrective surgery is performed, a critical point arises: the border between the instrumented area of the spine and the area that remains free. This border is the area where one of patients' major complications occurs. A research team led by Universitat Pompeu Fabra, with the Hospital del Mar, has managed to improve the accuracy of predicting the risk of the onset of this affectation, which may contribute to improving spinal surgeries. The research has enjoyed the collaboration of the Vall d'Hebron Research Institute, the Galeazzi Orthopaedic Institute in Milan and the Shulthess Klinik in Zurich (Switzerland).
more information
-
July, 23rd 2023 - Press notes
Cannabis use disorder (CUD) affects over 14 million individuals in the US. Despite the urgent need, there are no FDA-approved medications to treat CUD; behavioral treatments have shown limited benefit.
AEF0117 is the first of a new pharmacologic class, type 1 cannabinoid receptor signaling-specific inhibitors (CB1-SSi), with a unique mechanism of action and greater safety and efficacy than prior generations of CB1 inhibitors. In a phase 2a clinical study in volunteers with CUD, AEF0117 produced statistically significant reductions in the positive subjective and reinforcing effects of smoked cannabis.
more information